Melatonin receptor heterodimerization in a photoreceptor-like cell line endogenously expressing melatonin receptors

Aida Sánchez-Bretaña, Ting-Chung Suen, Kenkichi Baba, Jason DeBruyne, Gianluca Tosini

Department of Pharmacology and Toxicology and Neuroscience Institute, Morehouse School of Medicine, Atlanta, GA

Purpose: Melatonin signaling plays an important role in the modulation of retinal physiology and photoreceptor viability during aging. In this study, we investigated whether 661W cells—a photoreceptor-like cell that endogenously expresses melatonin receptor type 1 (MT₁) and melatonin receptor type 2 (MT₂) receptors—represent a useful model for studying the biology of heterodimerization and signaling of MT₁/₂ receptors.

Methods: 661W cells were cultured, and MT₁/MT₂ heterodimerization in 661W cells was assessed with proximity ligation assay. MT₁ was removed from the 661W cells using the MT₁-CRISPR/Cas9 system. Melatonin receptor signaling was investigated by measuring cAMP levels and activation of the AKT-FoxO1 pathway.

Results: The results demonstrated that heterodimerization of MT₁ and MT₂ receptors occurs in 661W cells. The pathways activated by MT₁/MT₂ heterodimer (MT₁/₂h) in 661W cells are similar to those previously reported in mouse photoreceptors. Disruption of the heterodimer formation by genetically ablating MT₁ from 661W cells abolished the activation of melatonin signaling in these cells.

Conclusions: The data indicated that in 661W cells, MT₁ and MT₂ receptors are functional only when they are associated in a heteromeric complex, as occurs in mouse photoreceptors. 661W cells represent a useful model for studying the mechanism underlying MT₁/MT₂ heterodimerization.

Retinal melatonin is synthesized by the photoreceptors of many vertebrate species via a well-defined biosynthetic pathway [1]. In the retina, as in the pineal gland, melatonin synthesis occurs during the night [2] and is under direct control of the circadian clock [3,4]. Transcriptional and post-translational mechanisms ensure that melatonin levels are maintained at extremely low levels during the light phase of the light-dark cycle [5,6], and appear to be important, as high melatonin levels during the light phase may be deleterious for photoreceptor cells [7,8]. Retinal melatonin acts mainly via the activation of two different G protein-coupled receptors (GPCRs) known as melatonin receptor type 1 (MT₁) and MT₂ [9-13] which are present in the retina [14-17].

A previous study [14] reported that in murine photoreceptors MT₁ and MT₂ appear to form functional heterodimers (MT₁/₂h). This MT₁/₂h signals via the activation of the Phospholipase C (PLC)- Protein Kinase-ζ (PKC-ζ; Life technologies, Carlsbad, CA) pathway [14,18], and accumulating experimental evidence indicates that, at least in the mouse, MT₁/₂h modulates the daily rhythm in the a- and b-waves of the scotopic electroretinogram and thus, light sensitivity [14,18]. Furthermore, it has been reported that the nocturnal activation of MT₁/₂h signaling in photoreceptors protects rods and cones during aging by modulating the AKT-FoxO1 survival pathway [19]. However, a significant barrier to full understanding of MT₁/₂h signaling is the lack of a cell line in which the specific signaling of each melatonin receptor (i.e., MT₁, MT₂, and MT₁/₂h) can be studied.

Recently, a cone-like photoreceptor cell line (661W cells) was developed [20], and has been recognized as a useful model for studying photoreceptor cell biology [21-25]. Several studies using 661W cells have partially elucidated the molecular mechanisms underlying photoreceptor cell metabolism [24-26] and cell death following light exposure [27-31] or oxidative stress [32-34]. Our laboratory recently showed that 661W cells express functional MT₁ and MT₂ receptors, and the activation of these receptors by exogenous melatonin can partially protect them from H₂O₂-induced cell death by inhibiting the AKT-FOSO1-Fas/Fasl-caspase-3 pathway [35].

Although the formation and signaling of MT₁/₂h have been previously studied, those experiments used overexpression of MT₁/MT₂ in human embryonic kidney (HEK) 293T cells [36,37] or mouse photoreceptors [14]. In this study, we investigated whether endogenous MT₁ and MT₂ receptors form MT₁/₂h in 661W cells and studied the intracellular pathways activated by this GPCR heterodimer.
**METHODS**

*Cell culture*: 661W cells were grown in Dulbecco's Modified Eagle's medium (DMEM; Gibco, Life Technologies, Carlsbad, CA) supplemented with 5% fetal bovine serum (Gibco) and 1% penicillin/streptomycin, at 37 °C in a 5% CO₂ humidified atmosphere [35]. Cells were seeded in six-well plates or 75-mm flasks at a concentration of 1 × 10⁴ cells in a volume of 3–10 ml of media and expanded to approximately 50% to 90%, depending on the experiment.

In the proximity ligation assay (PLA) and immunofluorescence experiments, cells were seeded in sterile glass chamber slides and allowed to expand to 50% confluence. The genetic profile of the cells was established by IDEXX Bioresearch (Columbia, MO). Nine short tandem repeat (STR) loci including a gender-determining locus were analyzed (Appendix 1) [35].

*Drug stock preparation*: Melatonin (MEL; 8 mg/ml, Sigma, St. Louis, MO) and forskolin (1 μM; Sigma) stock solutions were prepared in absolute ethanol and then diluted to the working concentration in DMEM. Forskolin (25 mM; Sigma), luzindole (LUZ; 10 mM; Tocris, Ellisville, MO) and IIK7 (30 mg/ml; Sigma) stock solutions were prepared in dimethyl sulfoxide (DMSO) and diluted to working solutions in DMEM.

*Colocalization of MT₁ and MT₂ in 661W cells*: Cells were directly washed in PBS (1X; KCl 2.67 mM, KH₂PO₄ 1.47 mM, NaCl 139.9 mM, Na₂HPO₄ 8.1 mM, pH 7.4) and fixed in cold acetone for 2 min. Once fixed, the cells were washed in PBS twice for 10 min and incubated in BLOXALL (Vector Laboratories, Burlingame, CA) to block endogenous peroxidases and phosphatases for 10 min. Then, samples were washed twice with PBS for 10 min, blocked with PBS containing 0.02% Triton and 5% BSA (1 h at room temperature), and incubated with previously validated primary antibodies [37], MT₁ (0.004 mg/ml; rabbit, AMR-031; Alomone) and MT₂ (0.004 mg/ml; goat, SC13177; Santa Cruz Biotechnology), overnight at 4 °C. After incubation with primary antibodies, PLA was performed following the manufacturer's instructions (Sigma) with minor modifications. Briefly, samples were washed twice in PBS for 10 min and one time in PBS with 0.02% Triton for 5 min. Subsequently, samples were incubated with the PLA probes (1:5 in blocking solution) for 1 h at 37 °C. Then after two washes in wash buffer A for 5 min, samples were incubated with ligase validation solution for 30 min at 37 °C. After two washes in wash buffer A for 2 min, samples were incubated with polymerase solution for 100 min at 37 °C. After washing in wash buffer B for 10 min, samples were incubated with SYTOX green (1:10,000) for 1 min to stain cell nuclei. Finally, after washing in wash buffer B for 10 min and wash buffer B diluted (0.01X) for 1 min, samples were mounted with VECTASHIELD mounting medium. Slides were examined with a confocal microscope (Zeiss LSM700). Images were processed with Zeiss Cell software. Micrographs were generated in the TIFF format and adjusted linearly for light and contrast before being assembled on plates using Adobe Photoshop CS6 (San Jose, CA). To validate the MT₁ and MT₂ receptor antibodies, a secondary antibody control was used without the primary antibody, as well as an absorption control (by preincubating the antibody with its specific blocking peptide).

*Proximity ligation assay*: Cells were washed in PBS and fixed in cold acetone for 2 min. Then, the cells were washed in PBS twice for 10 min and incubated in BLOXALL (Vector Laboratories) to block endogenous peroxidases and phosphatases, for 10 min. Samples were then washed twice in PBS for 10 min, blocked with PBS containing 0.02% Triton and 5% BSA (1 h at room temperature), and incubated with previously validated primary antibodies [37], MT₁ (0.004 mg/ml; rabbit, AMR-031; Alomone) and MT₂ (0.004 mg/ml; goat, SC13177; Santa Cruz Biotechnology), overnight at 4 °C. After incubation with primary antibodies, PLA was performed following the manufacturer’s instructions (Sigma) with minor modifications. Briefly, samples were washed twice in PBS for 10 min and one time in PBS with 0.02% Triton for 5 min. Subsequently, samples were incubated with the PLA probes (1:5 in blocking solution) for 1 h at 37 °C. Then after two washes in wash buffer A for 5 min, samples were incubated with ligase validation solution for 30 min at 37 °C. After two washes in wash buffer A for 2 min, samples were incubated with polymerase solution for 100 min at 37 °C. After washing in wash buffer B for 10 min, samples were incubated with SYTOX green (1:10,000) for 1 min to stain cell nuclei. Finally, after washing in wash buffer B for 10 min and wash buffer B diluted (0.01X) for 1 min, samples were mounted with VECTASHIELD mounting medium. Slides were examined with a confocal microscope (Zeiss LSM700). Images were processed with Zeiss Cell software. Micrographs were generated in the TIFF format and adjusted linearly for light and contrast before being assembled on plates using Adobe Photoshop CS6 (San Jose, CA). To validate the MT₁ and MT₂ receptor antibodies, a secondary antibody control was used without the primary antibody, as well as an absorption control (by preincubating the antibody with its specific blocking peptide).

*Establishment of MT₂⁻⁻ cell lines using the CRISPR/Cas9 system*: A construct to knock out MT₁ receptor was purchased from Santa Cruz Biotechnology, Inc. (MEL-1B-R CRISPR/Cas9 KO plasmid). The MEL-1B-R CRISPR/Cas9 KO plasmid is a pool of three different gRNA plasmids with the following sequences: sc-434093 A: Sense: 5’-AAC CGC AAG CTG CCG AAC GC-3’; sc-434093 B: Sense: 5’-GCA GCG CCT AGT GTT CCA TA-3’; sc-434093 C: Sense: 5’-CGT CAC GGA TAA TGG CCA CA-3’. The 661W cells cultured on a 12-well plate were cotransfected with 0.5 μg of the MEL-1B-R CRISPR/Cas9 plasmid and 0.5 μg of the MEL-1B-R CRISPR/Cas9 plasmid.
HDR plasmid, which included a puromycin resistance gene (used for selection of colonies) and red fluorescent protein (RFP) to detect the correct insertion of the plasmid in the genome (Santa Cruz Biotechnology, Inc.). After selection in medium containing puromycin (4 µg/ml), only cells with RFP signals were isolated.

Detection of MT_2 mRNA: RNA extraction (TRI® Reagent method, DNase treatment (Promega, Madison, WI), cDNA synthesis, and conventional PCR (One Step SYBR® Prime-Script™ RT–PCR kit II, Takara, Mountain View, CA) reactions were performed following the manufacturer’s instructions. About 200 ng of RNA obtained from 30,000 to 40,000 cells was used to perform the one-step Reverse transcription polymerase chain reaction (RT-PCR) reactions that were developed in a final volume of 50 µl. The resulting PCR product (MT_1 primers, F: 5’-ATC GTG GTG GAC ATT CTG GG-3’; R: 5’-TGC CAC AGC TAA ACT CAC CA-3’; expected size of 105 bp; MT_2 primers, F: 5’-GAT GAC AAG CAG GTT CCC CA-3’; R: 5’-GCG CAC CTT GTG CAT CTA TC-3’, expected size of 109 bp) was run in an agarose 1.5% Tris- Acetate-EDTA buffer (TAE) gel and visualized by using the EZ-Vision kit (Amresco, VWR, Solon, OH) in an ultraviolet (UV) transilluminator.

cAMP formation assay: To test the functionality of the melatonin receptors, 661W and 661W-MT_−/− cells were treated with forskolin (1 µM) alone or in combination with MEL (10, 100, or 1,000 nM) or IIK7 (1, 10, 100, or 1,000 nM) for 15 min. The cAMP levels were determined with enzyme-linked immunosorbent assay (ELISA) using a commercial kit (Enzo Life Sciences, St. Petersburg, FL) following the manufacturer’s instructions. The limit of detection calculated in our laboratory was 4.09 ng/ml.

AKT and ERK1/2 activation assay: To test the intracellular pathways activated by MEL, 661W and 661W-MT_−/− cells were treated with MEL (100 nM) for 90 min. Total AKT, phospho-AKT (S473; P-AKT), total FoxO1, phospho-FoxO1 (S256; P-FoxO1), total ERK1/2, and phospho-ERK1/2 (T202/Y204; P-ERK1/2) were measured with ELISA using commercial kits (RayBiotech, Peachtree Corners, GA; LSBio and Life Technologies, respectively), following the manufacturer’s instructions with minor modifications. After the proteins were extracted, the samples were loaded in the specific ELISA plates to measure the AKT/FoxO1 and ERK1/2 pathways, respectively, and the manufacturer’s guidelines were followed.

Data analysis: A one-way ANOVA followed by the post-hoc Student–Newman–Keuls (SNK) test was performed for data from the viability and gene expression experiments. A p value of less than 0.05 was considered statistically significant in all tests.

RESULTS

MT_1 and MT_2 receptors heterodimerize in 661W cells: MT_1 and MT_2 were detected in 661W cells, and colocalization was found (Figure 1, upper panels). To determine the presence of MT_1/2h, we performed PLA [14]. As shown in the lower panels in Figure 1, a PLA positive signal was detected in 661W cells, thus suggesting an interaction between these endogenously expressed receptors. To confirm that this signal was specific to heterodimer formation, the CRISPR/Cas9 system (Figure 2) was used to disrupt the heterodimer formation by knocking out the MT_1 receptor in the 661W cells (661W-MT_−/−). MT_2 mRNA and immunoreactivity were completely ablated in 661W-MT_−/− cells (Figure 3, upper panels) whereas MT_1 receptor mRNA and immunoreactivity were still present at levels comparable to those observed in the 661W cells (Figure 3, middle panels). As expected, we could not detect MT_1/2h formation with PLA in 661W-MT_−/− cells (Figure 3, lower panels), confirming the specificity of this assay for the heterodimer. Thus, the data suggest that endogenously expressed MT_1 and MT_2 form heterodimers.

Administration of exogenous melatonin activates cAMP signaling in 661W cells: To determine whether 661W cells respond to melatonin, we tested whether administration of exogenous MEL was able to inhibit the forskolin-induced cAMP production in 661W cells [14]. As expected, MEL was able to suppress the forskolin-induced cAMP production in a dose-dependent manner (Figure 4A, p<0.05). When the MEL agonist, IIK7 was used, the effect was observed only at 1,000 nM (Figure 4B), a concentration in which MT_1 and MT_2 receptors are activated [14]. The suppression of cAMP production by MEL (100 nM) was blocked in a dose-dependent manner when The 661W cells were pretreated with the melatonin antagonist LUZ (1 and 10 µM; Figure 4C, p>0.05). Similarly, the reduction in the forskolin-induced cAMP production by MEL was abolished in the 661W-MT_−/− cells (Figure 4D, p>0.05).

MEL signaling in 661W cells is comparable to that observed in the murine retina: Previous work by our laboratory showed that MEL induces phosphorylation of AKT and FoxO1 in murine photoreceptors. Likewise, we found that administration of exogenous MEL to 661W cells increased the phosphorylation of AKT/FoxO1 (Figure 5A, p<0.05) and ERK1/2 (Figure 5B; p>0.05). AKT/FoxO1 and ERK1/2 were also phosphorylated in response to IIK7 administration (Figure 5, p<0.05), but only at a concentration of 1,000 nM which activates MT_1 and MT_2 receptors [14].
Figure 1. MT$_1$ and MT$_2$ form heterodimers in 661W cells. Upper panels: Immunofluorescence for melatonin receptor type 1 (MT$_1$) and MT$_2$ receptors and colocalization. Scale bars = 100 µm. Lower panels: Proximity ligation assay (PLA) showing the MT$_1$/MT$_2$ interaction (positive signal shown as red dots in the right panel). Cell nuclei are shown in green. Scale bars: left and center = 100 µm, right = 50 µm.

Figure 2. RFP signal in 661W cells transfected with the MEL-1B-R HDR plasmid. 661W cells were cotransfected with MEL-1B-R HDR and MEL-1B-R CRISPR/Cas9 KO. After 2–3 weeks of selection in medium containing puromycin, colonies were picked to become individual cell lines. Expression of red fluorescence protein indicates the successful homology directed insertion at the melatonin receptor type 2 (MT$_2$) locus. A: Bright-field. B: Bright-field plus red fluorescent protein (RFP). Scale bar = 100 µm.
However, removal of MT$_2$ receptors in 661W-MT$_2$-KO cells completely blocked these effects, as exogenous MEL could no longer induce phosphorylation of AKT/FoxO1 (Figure 5A,B, $p>0.05$).

**DISCUSSION**

Heterodimerization of GPCRs is a new and important topic of investigation as GPCR heteromers may represent an important therapeutic target for the development of new drugs [12]. Previous studies have shown that melatonin receptors

---

**Figure 3.** Genetic ablation of MT$_2$ with CRISPR/Cas9 system does not affect MT$_1$ mRNA or protein. Top panels: cDNA from 661W and 661W-MT$_2$−/− cells was analyzed with reverse transcriptase PCR (RT–PCR) to detect MT$_1$ (left) and MT$_2$ (right) expression. Middle panels: Immunofluorescence was performed in 661W and 661W-melatonin receptor type 2 (MT$_2$)$^{-/-}$ cells to detect MT$_1$ (left) and MT$_2$ (right) proteins. The positive signal of each receptor is shown in green, and nuclei are counterstained in red. Lower panel: The presence or absence of MT$_1$/MT$_2$ heterodimer in 661W and 661W-MT$_2$−/− cells was assessed with proximity ligation assay (PLA; positive signal in red), and nuclei were counterstained in green. MT$_1$ expression (transcript and protein) was detected in 661W and 661W-MT$_2$−/− cells, whereas MT$_2$ expression (transcript and protein) was detected only in 661W cells. Accordingly, MT$_{1/2}$h was found only in 661W cells. Scale bars = 100 µm.
can form MT\textsubscript{1/2h} heterodimers when overexpressed in HEK 293 cells [36,37] or mouse photoreceptors [14]. However, although the formation of MT\textsubscript{1/2h} was detected, these data were obtained by overexpressing MT\textsubscript{1} and MT\textsubscript{2} in either the HEK 293 or photoreceptor cells (myc/flag system), and therefore, it is still questionable whether MT\textsubscript{1} and MT\textsubscript{2} can form MT\textsubscript{1/2h} under physiologic conditions.

The results in 661W cells, which endogenously express melatonin receptors [35], suggest these receptors form functional MT\textsubscript{1/2h} under a physiologic setting. Intriguingly, the prevention of the formation of heterodimers by removal of MT\textsubscript{2} receptors alone completely abolished the activation of intracellular pathways normally activated by melatonin, thus suggesting that in these cells (as reported for mouse photoreceptors [14]) melatonin signaling can be activated only when both receptors are present.

The present data provide experimental evidence supporting the formation of MT\textsubscript{1/2h} in 661W cells. We showed that the PLA signal is present only when both receptors are present in these cells (Figure 1), and the results obtained with 661W-MT\textsubscript{2} KO indicate that the presence of MT\textsubscript{2} is required to respond to melatonin stimulation (Figure 3, Figure 4, Figure 5). Finally, melatonin action can be blocked only when the agonist LUZ is present at a concentration that blocks both receptors [14] (Figure 4), and the melatonin agonist IIK7 can activate melatonin signaling only at a concentration that activates both receptors [14].

In this context, although MT\textsubscript{1} receptors mRNA and immunoreactivity were unaffected in 661W-MT\textsubscript{2}−/− cells (Figure 3), administration of exogenous MEL did not activate any of the intracellular signaling pathways known to be activated by melatonin [38]. Although we have not tested
whether removal of MT1 from these cells would produce results similar to those observed in 661W-MT2−/− cells, we believe that removal of the MT1 also abolishes melatonin signaling. This expectation is based on our previous in vivo study [14] in which we showed that in murine photoreceptors the lack of either MT1 or MT2 completely prevents the action of melatonin on scotopic ERGs [14,39] and the protective action of melatonin on photoreceptors during aging [19]. Thus, it seems that in cells where MT1 and MT2 are coexpressed in the same cells under natural conditions, the receptors form obligate heterodimers where if one receptor is removed or mutated the other receptor cannot activate the intracellular signaling in response to the ligand. Thus, such a result suggests that the specific cellular environment may have an important role in determining the response of GPCR heterodimers.

Melatonin receptors are distributed in many organs and tissues where they mediate many different physiologic functions [11,12]. However, to date, the heterodimerization of these receptors has been reported in only retinal photoreceptors [14], and because 661W cells are derived from mouse photoreceptors, it is not surprising that they also express MT1/2. A recent study reported that 661W cells may represent retinal ganglion precursors, with characteristics of ganglion and photoreceptor cells [38]. The present data showing that MT1/2 are in these cells further suggest that the cellular identity of the 661W cells must be similar to murine photoreceptors.

Taken together, these results indicate the presence of MT1/2 in 661W cells demonstrates that these heterodimers can form under physiologic conditions. As previously observed in mouse photoreceptors, melatonin signaling in 661W cells can occur only when both receptors are present. Thus, the present study results indicate that 661W cells may represent a new and important tool for studying MT1/2, and more generally, the biology of GPCR heterodimerization.

APPENDIX 1. STR ANALYSIS.
To access the data, click or select the words “Appendix 1.”

ACKNOWLEDGMENTS
This work was supported by grants from the National Institutes of Health Grants EY022216, EY026291 to G.T., GM 116760 to B.K. and by 5U54NS083932, S21MD000101, G12-RR03034, U54RR026137 to Morehouse School of Medicine. The authors wish to express their gratitude to Dr. Muayyad Al-Ubaidi (University of Houston) for providing the 661W cells.

REFERENCES
1. Klein DC, Coon SL, Roseboom PH, Roseboom PH, Weller JL, Bernard M, Gastel JA, Zatz M, Iuvone PM, Rodriguez IR, Bégay V, Falcón J, Cahill GM, Cassone VM, Baler R. The melatonin rhythm-generating enzyme: molecular regulation of serotonin N-acetyltransferase in the pineal gland. Recent Prog Horm Res 1997; 52:307-57. [PMID: 9238858].
2. Tosini G, Baba K, Hwang CK, Iuvone PM. Melatonin: an underappreciated player in retinal physiology and pathophysiology. Exp Eye Res 2012; 103:82-9. [PMID: 22960156].
3. Cahill GM, Besharse JC. Circadian clock functions localized in Xenopus retinal photoreceptors. Neuron 1993; 10:573-7. [PMID: 8476609].
4. Zawilska JB, Iuvone PM. Melatonin synthesis in chicken retina: effect of kainic acid-induced lesions on the diurnal
rhythm and D2-dopamine receptor-mediated regulation of serotonin N-acetyltransferase activity. Neurosci Lett 1992; 135:71-4. [PMID: 1347416].

5. Fukuhara C, Dirden JC, Tosini G. Photic regulation of melatonin in rat retina and the role of proteosomal proteolysis. Neuroreport 2001; 12:3833-7. [PMID: 11726804].

6. Fukuhara C, Liu C, Ivanova TN, Chan GC, Storm DR, Iuvone PM, Tosini G. Gating of the cAMP signaling cascade and melatonin synthesis by the circadian clock in mammalian retina. J Neurosci 2004; 24:1803-11. [PMID: 14985420].

7. Wiechmann AF, O’Steen WK. Melatonin increases photoreceptor susceptibility to light-induced damage. Invest Ophthalmol Vis Sci 1992; 33:1894-902. [PMID: 1582795].

8. Sugawara T, Sieving PA, Iuvone PM, Bush RA. The melatonin antagonist luzindole protects retinal photoreceptors from light damage in the rat. Invest Ophthalmol Vis Sci 1998; 39:2458-65. [PMID: 9804154].

9. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXCV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010; 62:343-80. [PMID: 20605968].

10. Reppert SM. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms 1997; 12:528-31. [PMID: 9406026].

11. Tosini G, Owino S, Guillame J-L, Jockers R. Melatonin receptors: latest insights from mouse models. BioEssays News Rev Mol Cell Dev Biol 2014; 36:778-87. .

12. Cecon E, Oishi A, Jockers R. Melatonin receptors: molecular pharmacology and signaling in the context of system bias. Br J Pharmacol 2018; 175:3263-80. [PMID: 28707298].

13. Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP. Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol 2016; 173:2702-25. [PMID: 27314810].

14. Baba K, Benleulmi-Chaachoua A, Journé AS, Kamal M, Guil-laume JL, Dussaud S, Gibbou F, Yetou K, Liu C, Contreras-Alcantara S, Jockers R, Tosini G. Heteromeric MT1/MT2 melatonin receptors modulate photoreceptor function. Sci Signal 2013; 6:ra89-[PMID: 24106342].

15. Scher J, Wankiewicz E, Brown GM, Fujieda H. MT(1) melatonin receptor in the human retina: expression and localization. Invest Ophthalmol Vis Sci 2002; 43:889-97. [PMID: 11867612].

16. Savaskan E, Jockers R, Ayoub M, Angeloni D, Fraschini F, Flammer J, Eckert A, Muller-Spahn F, Meyer P. The MT2 melatonin receptor subtype is present in human retina and decreases in Alzheimer’s disease. Curr Alzheimer Res 2007; 4:47-51. [PMID: 17316165].

17. Fujieda H, Hamadanizadeh SA, Wankiewicz E, Pang SF, Brown GM. Expression of mt1 melatonin receptor in rat retina: evidence for multiple cell targets for melatonin. Neuroscience 1999; 93:793-9. [PMID: 10465462].

18. Piano I, Baba K, Claudia Gargini, Tosini G. Heteromeric MT1/MT2 melatonin receptors modulate the scotopic electroretinogram via PKCζ in mice. Exp Eye Res 2018; 177:50-4. [PMID: 30059666].

19. Giansesini C, Hiragaki S, Laurent V, Hicks D, Tosini G. Cone Viability Is Affected by Disruption of Melatonin Receptors Signaling. Invest Ophthalmol Vis Sci 2016; 57:94-104. [PMID: 26780313].

20. al-Ubaidi MR, Font RL, Quiambao AB, Keener MJ, Liou GI, Overbeek PA, Baehr W. Bilateral retinal and brain tumors in transgenic mice expressing simian virus 40 large T antigen under control of the human interphotoreceptor retinoid-binding protein promoter. J Cell Biol 1992; 119:1681-7. [PMID: 1334963].

21. Al-Ubaidi MR, Matsumoto H, Kurono S, Singh A. Proteomics profiling of the cone photoreceptor cell line, 661W. Adv Exp Med Biol 2008; 613:301-11. [PMID: 18188958].

22. Duricka DL, Brown RL, Varnum MD. Defective trafficking of cone photoreceptor CNG channels induces the unfolded protein response and ER-stress-associated cell death. Biochem J 2012; 441:685-96. [PMID: 21992067].

23. Tan E, Ding X-Q, Saadi A, Agarwal N, Naash MI, Al-Ubaidi MR. Expression of Cone-Photoreceptor–Specific Antigens in a Cell Line Derived from Retinal Tumors in Transgenic Mice. Invest Ophthalmol Vis Sci 2004; 45:764-8. [PMID: 14985288].

24. Farrell SMJ, Groeger G, Bhatt L, Finnegan S, O’Brien CJ, Cotter TG. bFGF-mediated redox activation of the PI3K/Akt pathway in retinal photoreceptor cells. Eur J Neurosci 2011; 33:632-41. [PMID: 21219477].

25. Ozaki T, Nakazawa M, Yamashita T, Tomita H, Ebina Y, Ishiguro S. Decrease of ATP by mitochondrial m-calpain inhibitory peptide in the rat retinas. Cell Struct Funct 2013; 38:207-23. [PMID: 23965546].

26. Layton CJ. Diabetic levels of glucose increase cellular reducing equivalents but reduce survival in three models of 661W photoreceptor-like cell injury. BMC Ophthalmol 2015; 15:174-[PMID: 26653778].

27. Natoli R, Rutar M, Lu YZ, Chu-Tan JA, Chen Y, Saxena K, Madigan M, Valter K, Provis JM. The Role of Pyruvate in Protecting 661W photoreceptor-like cell injury. Curr Eye Res 2016; 41:1473-81. [PMID: 27210922].

28. Krishnamoorthy RR, Crawford MJ, Chaturvedi MM, Jain SK, Aggarwal BB, Al-Ubaidi MR, Agarwal N. Photo-oxidative stress down-modulates the activity of nuclear factor-kappaB via involvement of caspase-1, leading to apoptosis of photoreceptor cells. J Biol Chem 1999; 274:3734-43. [PMID: 9920926].

29. Chen W-J, Wu C, Xu Z, Kause Y, Hara H, Duh EJ. Nrf2 protects photoreceptor cells from photo-oxidative stress induced by blue light. Exp Eye Res 2017; 154:151-8. [PMID: 27923559].

30. Chang Q, Peter ME, Grassi MA. Fas ligand-Fas signaling participates in light-induced apoptotic death in photoreceptor
31. Kuse Y, Tsuruma K, Kanno Y, Shimazawa M, Hara H. CCR3 Is Associated with the Death of a Photoreceptor Cell-line Induced by Light Exposure. Front Pharmacol 2017; 8:207-[PMID: 28458639].

32. Fabiani C, Zulueta A, Bonezzi F, Casas J, Ghidoni R, Signorelli P, Caretti A. 2-Acetyl-5-tetrahydroxybutyl imidazole (THI) protects 661W cells against oxidative stress. Naunyn Schmiedebergs Arch Pharmacol 2017; 390:741-51. [PMID: 28409209].

33. Mackey AM, Sanvicens N, Groeger G, Doonan F, Wallace D, Cotter TG. Redox survival signalling in retina-derived 661W cells. Cell Death Differ 2008; 15:1291-303. [PMID: 18404155].

34. Chen H, Tran J-TA, Anderson RE, Mandal MNA. Caffeic acid phenethyl ester protects 661W cells from H2O2-mediated cell death and enhances electroretinography response in dim-reared albino rats. Mol Vis 2012; 18:1325-38. [PMID: 22690111].

35. Sánchez-Bretaño A, Baba K, Janjua U, Piano I, Gargini C, Tosini G. Melatonin partially protects 661W cells from H2O2-induced death by inhibiting Fas/FasL-caspase-3. Mol Vis 2017; 23:844-52. [PMID: 29259391].

36. Ayoub MA, Couturier C, Lucas-Meunier E, Angers S, Fossier P, Bouvier M, Jockers R. Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem 2002; 277:21522-8. [PMID: 11940583].

37. Jilg A, Bechstein P, Saade A, Dick M, Li TX, Tosini G, Rami A, Zemmar A, Stehle JH. Melatonin modulates daytime-dependent synaptic plasticity and learning efficiency. J Pineal Res 2019; 66:e12553-[PMID: 30618149].

38. Sayyad Z, Sirohi K, Radha V, Swarup G. 661W is a retinal ganglion precursor-like cell line in which glaucoma-associated optineurin mutants induce cell death selectively. Sci Rep 2017; 7:16855-[PMID: 29203899].

39. Baba K, Pozdeyev N, Mazzoni F, Contreras-Alcantara S, Liu C, Kasamatsu M, Martinez-Merlos T, Strettoi E, Iuvone PM, Tosini G. Melatonin modulates visual function and cell viability in the mouse retina via the MT1 melatonin receptor. Proc Natl Acad Sci USA 2009; 106:15043-8. [PMID: 19706469].